U.S. Markets closed

Aeterna Zentaris Inc. (AEZS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.18+0.22 (+22.92%)
At close: 4:00PM EDT
People also watch
KERXCYCCCTICGALEAGEN
  • possible big news: Takeover
    Its cash($17 m) is more than SP ($16 m), and has a drug near FDA approval. Any drug company would love to have it if they are not fools.
  • Big news on the way ?
  • Just got a call from my people informing me that a limo full of #$%$ with blonde wigs just pulled up to AEZS HQ, followed by a catering truck.Looks like negotiations will last all night, probably the weekend.Tuesday's open should be VERY interesting.
    Imageyourreactiongifs
  • Merger Tuesday!?!
  • NEWS out over weekend - BUY now !!!
    Ya FILTHY ANIMALS.
    Imagewelele
  • Things seem to be getting overextended for AEZS. Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awe-someSTOCKS.
  • FDA approve ? Maybe
    Dead Cat Wake up ?? Maybe
    big Guys ruuning out before Bad News ? Maybe

    but I think a big FDA news will Hit next week

    if FDA approve .... don't sell less that $50+
  • Macrilen ?
    Imagemarci1900
  • Going to $5 when news about Macrilen are out ?
  • https://ca.finance.yahoo.com/news/options-market-predicting-spike-aeterna-124712695.html

    Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock?
    Investors in Aeterna Zentaris Inc. (AEZS) need to pay close attention to the stock based on moves in the options market lately.
    ca.finance.yahoo.com
  • SMOKING !!!
    Buy, buy, BUY!
    Ya Filthy Animals!
    Imagewildestdreamsincrediblethings
  • THESMART PEOPLE ALWAYTAKE MONEY OFF THETABLE SO SHOULD YOU SO SHOULD YOU GET OUTOUTBEFORETHISCRASH CRASHBACK BELOW $1 RUN RUN TO THEEXIT EXIT DOOR BEWVERYVERY AFRAIDF TO LOSSALOTLOT OF MONEY NOW
  • If you KNUCKLE HEADS listened to me, you'd be UP at least 15% by now.
    Ya FILTHY ANIMALS!
    Buy, buy, BUY !!!
    Imagekickassanddisturbed
  • Putting out pumping news to crash!
  • BAAAMMM !!!!
    Last call ....... buy, buy, BUY !!!
    You SWINE!
    Imagecrap-userrname16
  • stinking carcass of a dead company.
  • Buy, buy, BUY !!!
    Imagepadfootnprongs21
  • Prepare for BLAST OFF, you FILTHY ANIMALS !!!
    Imagecinema-boheme
  • See why biotech/pharma shareholders are adding this breakthrough wound care to their portfolio.

    • BioLargo’s 10Q states their Advanced Wound Care products are ready, all studies successfully completed, and they expect to file a 510K with FDA in less than 90 days
    • Woundcare market is over $6 Billion with high growth rate
    • Tanya Rhodes, ex VP of Smith & Nephew Wound Care Product Development is leading the BLGO/Clyra Medical 510K filing
    • BLGO/Clyra Medical Wound Care Products promote healing substantially better than competing products, fight infection better than competing products, are effective against resistant microbials, and are low cost
    • Sales could commence in first half of 2018
    • Sales and or licensing agreement/s could be very significant
    • Company is now commercializing several other disruptive products in large markets

    http://www.clyramedical.com

    https://www.sec.gov/Archives/edgar/data/880242/000143774917009469/blgo20170331_10q.htm

    Clyra Medical | Make Life Better
    www.clyramedical.com
  • BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 20+ BAGGER POTENTIAL !!!
    AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 11 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.18

    MUST WATCH to realize the MONSTER POTENTIAL HERE
    https://www.dukascopy.com/tv/en/view/204408#00

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018